Clinical trial · no report yet · Phase 3
IMpassion030
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- NCT03498716 ↗
- Terminated
- Hoffmann-La Roche
- 41 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 24 | |
| Podcasts | 9 | |
| YouTube | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab; Paclitaxel; Dose-dense Doxorubicin or dose-dense Epirubicin; Cyclophosphamide
- Arms
- Atezolizumab + Chemotherapy · Experimental
- Chemotherapy · Active comparator
- Enrollment
- 2,199
- Primary outcomes
- Invasive Disease-Free Survival (iDFS)
- Sponsor
- Hoffmann-La Roche with Breast International Group, Alliance Foundation Trials, LLC., Jules Bordet Institute, Frontier Science & Technology Research Foundation, Inc.
- Start
- Aug 2, 2018
- Primary completion
- Aug 14, 2023
- Results posted
- Yes
- Registry record
- NCT03498716 · updated Aug 21, 2024
Publications
linked from the registry- Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Lee SC, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam EN, Gonzalez Farre X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. JAMA. 2025 Jan 30;333(13):1150-60. doi: 10.1001/jama.2024.26886. Online ahead of print. PubMed 39883436
- Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. PubMed 32450725